Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample.
Kelly Allott, Walid Yassin, Luis Alameda, Tashrif Billah, Owen Borders, Kate Buccilli, Ricardo E Carrión, Rolando I Castillo-Passi, Kang Ik K Cho, Kota Chin, Michael J Coleman, Beau-Luke Colton, Sebastián Corral, Dominic Dwyer, Kristina Ballestad Gundersen, Ruben C Gur, Gil D Hoftman, Grace R Jacobs, Sinead Kelly, Kathryn E Lewandowski, Patricia J Marcy, Priya Matneja, Danielle McLaughlin, Angela R Nunez, Setari Parsa, Nora Penzel, Susan Ray, Jenna M Reinen, Kosha Ruparel, Michael S Sand, Gennarina Santorelli, Johanna Seitz-Holland, Jessica Spark, Zailyn Tamayo, Andrew Thompson, Sophie Tod, Cassandra M J Wannan, Alana Wickham, Stephen J Wood, Eirini Zoupou, Jean Addington, Alan Anticevic, Celso Arango, Nicholas J K Breitborde, Matthew R Broome, Kristin S Cadenhead, Monica E Calkins, Eric Yu Hai Chen, Jimmy Choi, Philippe Conus, Cheryl M Corcoran, Barbara A Cornblatt, Lauren M Ellman, Paolo Fusar-Poli, Pablo A Gaspar, Carla Gerber, Louise Birkedal Glenthøj, Leslie E Horton, Christy Lai Ming Hui, Joseph Kambeitz, Lana Kambeitz-Ilankovic, Matcheri Keshavan, Sung-Wan Kim, Nikolaos Koutsouleris, Jun Soo Kwon, Kerstin Langbein, Daniel Mamah, Covadonga M Diaz-Caneja, Daniel H Mathalon, Vijay A Mittal, Merete Nordentoft, Godfrey D Pearlson, Diana O Perkins, Jesus Perez, Albert R Powers, Jack Rogers, Fred W Sabb, Jason Schiffman, Jai L Shah, Steven M Silverstein, Stefan Smesny, Gregory P Strauss, Judy L Thompson, Rachel Upthegrove, Swapna K Verma, Jijun Wang, Daniel H Wolf, Ofer Pasternak, Sylvain Bouix, Patrick D McGorry, John M Kane, Rene S Kahn, Carrie E Bearden, Martha E Shenton, Scott W Woods, Barnaby Nelson, William S Stone
{"title":"Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample.","authors":"Kelly Allott, Walid Yassin, Luis Alameda, Tashrif Billah, Owen Borders, Kate Buccilli, Ricardo E Carrión, Rolando I Castillo-Passi, Kang Ik K Cho, Kota Chin, Michael J Coleman, Beau-Luke Colton, Sebastián Corral, Dominic Dwyer, Kristina Ballestad Gundersen, Ruben C Gur, Gil D Hoftman, Grace R Jacobs, Sinead Kelly, Kathryn E Lewandowski, Patricia J Marcy, Priya Matneja, Danielle McLaughlin, Angela R Nunez, Setari Parsa, Nora Penzel, Susan Ray, Jenna M Reinen, Kosha Ruparel, Michael S Sand, Gennarina Santorelli, Johanna Seitz-Holland, Jessica Spark, Zailyn Tamayo, Andrew Thompson, Sophie Tod, Cassandra M J Wannan, Alana Wickham, Stephen J Wood, Eirini Zoupou, Jean Addington, Alan Anticevic, Celso Arango, Nicholas J K Breitborde, Matthew R Broome, Kristin S Cadenhead, Monica E Calkins, Eric Yu Hai Chen, Jimmy Choi, Philippe Conus, Cheryl M Corcoran, Barbara A Cornblatt, Lauren M Ellman, Paolo Fusar-Poli, Pablo A Gaspar, Carla Gerber, Louise Birkedal Glenthøj, Leslie E Horton, Christy Lai Ming Hui, Joseph Kambeitz, Lana Kambeitz-Ilankovic, Matcheri Keshavan, Sung-Wan Kim, Nikolaos Koutsouleris, Jun Soo Kwon, Kerstin Langbein, Daniel Mamah, Covadonga M Diaz-Caneja, Daniel H Mathalon, Vijay A Mittal, Merete Nordentoft, Godfrey D Pearlson, Diana O Perkins, Jesus Perez, Albert R Powers, Jack Rogers, Fred W Sabb, Jason Schiffman, Jai L Shah, Steven M Silverstein, Stefan Smesny, Gregory P Strauss, Judy L Thompson, Rachel Upthegrove, Swapna K Verma, Jijun Wang, Daniel H Wolf, Ofer Pasternak, Sylvain Bouix, Patrick D McGorry, John M Kane, Rene S Kahn, Carrie E Bearden, Martha E Shenton, Scott W Woods, Barnaby Nelson, William S Stone","doi":"10.1038/s41537-025-00578-1","DOIUrl":null,"url":null,"abstract":"<p><p>Cognitive impairment occurs at higher rates in individuals at clinical high risk (CHR) for psychosis relative to healthy peers, and it contributes unique variance to multivariate prediction models of transition to psychosis. Such impairment is considered a core biomarker of schizophrenia. Thus, cognition is a key domain measured in the Accelerating Medicines Partnership® program for Schizophrenia (AMP SCZ initiative). The aim of this paper is to describe the rationale, processes, considerations, and final harmonization of the cognitive battery used in AMP SCZ across the two data collection networks. This battery comprises tests of general intellect and specific cognitive domains. We estimate premorbid intelligence at baseline and measure current intelligence at baseline and 2 years. Eight tests from the Penn Computerized Neurocognitive Battery (PennCNB), which measure verbal learning and memory, sensorimotor ability, attention, emotion recognition, working memory, processing speed, verbal memory, visual memory, and motor speed are administered repeatedly at baseline, and four follow-up timepoints over 2 years.</p>","PeriodicalId":74758,"journal":{"name":"Schizophrenia (Heidelberg, Germany)","volume":"11 1","pages":"49"},"PeriodicalIF":3.0000,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11933323/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Schizophrenia (Heidelberg, Germany)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1038/s41537-025-00578-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0
Abstract
Cognitive impairment occurs at higher rates in individuals at clinical high risk (CHR) for psychosis relative to healthy peers, and it contributes unique variance to multivariate prediction models of transition to psychosis. Such impairment is considered a core biomarker of schizophrenia. Thus, cognition is a key domain measured in the Accelerating Medicines Partnership® program for Schizophrenia (AMP SCZ initiative). The aim of this paper is to describe the rationale, processes, considerations, and final harmonization of the cognitive battery used in AMP SCZ across the two data collection networks. This battery comprises tests of general intellect and specific cognitive domains. We estimate premorbid intelligence at baseline and measure current intelligence at baseline and 2 years. Eight tests from the Penn Computerized Neurocognitive Battery (PennCNB), which measure verbal learning and memory, sensorimotor ability, attention, emotion recognition, working memory, processing speed, verbal memory, visual memory, and motor speed are administered repeatedly at baseline, and four follow-up timepoints over 2 years.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
